AKL-T01
AKL-T01 is a medical device with 7 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
1
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Digital Intervention for Post-Stroke Depression and Executive Dysfunction
Cognitive Training in Survivors of Covid-19: A Randomized Trial
Improving Cognitive Health in COVID-19 Survivors
Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01
Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents)
Clinical Trials (7)
A Digital Intervention for Post-Stroke Depression and Executive Dysfunction
Cognitive Training in Survivors of Covid-19: A Randomized Trial
Improving Cognitive Health in COVID-19 Survivors
Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01
Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents)
Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant
Software Treatment for Actively Reducing Severity of ADHD
All 7 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 7